Viewing Study NCT00560794


Ignite Creation Date: 2025-12-25 @ 1:38 AM
Ignite Modification Date: 2026-04-12 @ 8:34 AM
Study NCT ID: NCT00560794
Status: COMPLETED
Last Update Posted: 2015-01-26
First Post: 2007-11-19
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase II Study of the BiTEĀ® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Sponsor: Amgen Research (Munich) GmbH
Organization: